Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB)

Key Points

• Wedbush has lowered its Q3 2025 earnings per share (EPS) estimate for Biogen to $3.74, down from $3.76, maintaining a "Neutral" rating and a price target of $135.00.
• Biogen's recent quarterly earnings surpassed expectations with reported EPS of $5.47 and revenue of $2.65 billion, reflecting a significant year-over-year revenue increase of 7.3%.
• Institutional investors and hedge funds own approximately 87.93% of Biogen's stock, with several firms recently increasing their stakes in the company.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities research analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for shares of Biogen in a note issued to investors on Tuesday, October 14th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $3.74 per share for the quarter, down from their previous forecast of $3.76. Wedbush has a "Neutral" rating and a $135.00 price objective on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q4 2025 earnings at $3.43 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.93 by $1.54. The business had revenue of $2.65 billion for the quarter, compared to analysts' expectations of $2.32 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.Biogen's quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the business posted $5.28 earnings per share. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

BIIB has been the subject of several other research reports. Rothschild & Co Redburn increased their price target on shares of Biogen from $149.00 to $150.00 and gave the stock a "neutral" rating in a research report on Monday, October 6th. HC Wainwright increased their target price on Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Needham & Company LLC restated a "hold" rating on shares of Biogen in a research report on Wednesday, September 24th. Piper Sandler upped their price target on Biogen from $115.00 to $118.00 and gave the company a "neutral" rating in a research report on Friday, September 12th. Finally, William Blair reiterated an "outperform" rating on shares of Biogen in a research note on Wednesday, September 24th. Eleven investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Biogen currently has an average rating of "Hold" and a consensus price target of $180.69.

Biogen Trading Up 0.4%

Shares of BIIB stock opened at $145.31 on Wednesday. The firm has a fifty day moving average of $140.71 and a 200-day moving average of $131.23. The stock has a market cap of $21.31 billion, a price-to-earnings ratio of 13.89, a P/E/G ratio of 1.14 and a beta of 0.13. Biogen has a 52-week low of $110.04 and a 52-week high of $194.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 517 shares of the business's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the transaction, the insider owned 5,772 shares of the company's stock, valued at approximately $770,850.60. The trade was a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.18% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. IFM Investors Pty Ltd raised its stake in shares of Biogen by 4.9% in the third quarter. IFM Investors Pty Ltd now owns 37,490 shares of the biotechnology company's stock worth $5,150,000 after acquiring an additional 1,738 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Biogen by 9.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,049 shares of the biotechnology company's stock valued at $147,000 after buying an additional 94 shares during the period. Parcion Private Wealth LLC bought a new stake in shares of Biogen during the third quarter worth $227,000. Patton Fund Management Inc. acquired a new position in shares of Biogen during the third quarter valued at $259,000. Finally, Brighton Jones LLC boosted its holdings in Biogen by 27.7% in the third quarter. Brighton Jones LLC now owns 6,514 shares of the biotechnology company's stock valued at $912,000 after acquiring an additional 1,412 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.